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ABSTRACT PAGE

Posttranslational modifications by the small proteins ubiquitin and SUMO control the
localization, activity and degradation of intracellular substrates. In recent years our
knowledge of the crosstalk between the SUMO and ubiquitin systems has expanded
significantly as exemplified by a novel class of enzymes called SUMO-targeted Ubiquitin
Ligases (STUbLs). This study focuses on the Slx5/Slx8 heterodimer, a STUbL with an
important role in genome maintenace and regulation of SUMO-conjugate levels in
Saccharomyces cerevisiae. The Slx5/Slx8 STUbL relies on SUMO-interacting motifs
(SIMs) in Slx5 for substrate targeting and a carboxy-terminal RING domain in Slx5 and
Slx8 for substrate ubiquitylation. In budding yeast cells Slx5 and Slx8 reside in the nucleus,
form distinct foci, and can associate with double-stranded DNA (dsDNA) breaks. We
hypothesized that distinct targeting and protein interaction domains in Slx5 affect its
binding with substrates, Slx8, and SUMO.
Therefore, we constructed and analyzed
truncations of the Slx5 protein. Our structure function analysis revealed a specific domain
in Slx5 that is required for nuclear localization. A truncation mutant, Slx5(1-207), that lacks
this domain fails to enter the nucleus, accumulates in the cytosol, and is enriched at the
bud-neck of dividing yeast cells where it co-localizes with septin proteins. In a two-hybrid
assay Slx5(1-207) failed to interact with the septins Cdc3, Cdc11, and Shs1, but interacted
strongly with the SUMO ligase Siz1. Since Siz1 localizes to the bud-neck in a cell cyclespecific manner and is required for septin sumoylation we tested whether Slx5 functionally
interacts with Siz1. First, we found that both full-length and Slx5(1-207) interact robustly
with Slx5 in a two-hybrid assay and in co-precipitation assays. Second, deletion of SLX5
and SLX8 result in dramatically reduced septin sumoylation in G2/M arrested cells. Third,
a purified Siz1 protein is an in vitro ubiquitylation target of the Slx5/Slx8 STUbL. This study
provides the first evidence that STUbLs may regulate the sumoylation of cytosolic proteins
and functionally interact with the SUMO ligase Siz1 in vivo and in vitro.
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INTRODUCTION
Ubiquitin and SUMO
Eukaryotic cells have implemented a intricate and highly conserved
mechanism to modulate the function of specific proteins through the attachment
of two small modifying proteins called ubiquitin and SUMO (Small Ubiquitin-like
Modifier). SUMO and ubiquitin are the most prominent members of a conserved
family of post-translational modifiers called ubiquitin-like proteins (Ubls).
Members of the Ubl family share a three dimensional shape, the (3-GRASP fold,
as part of their conserved structure and have key roles in the suppression of
genomic instability and cell growth (as reviewed by Perry et al., 2008). These two
Ubls play various roles in regulating the half-life, activity, localization and
interactions of a plethora of proteins they are known to modify (Kerscher et al,
2006). Proteins modified by ubiquitin and SUMO play important roles in
processes including transcription, DNA repair, and cell cycle control to name a
few (Hochstrasser, 2009).

Processing ubiquitin and SUMO precursors
In mammals and yeast alike, ubiquitin is expressed as a polyubiquitin fusion
protein or as a fusion between ubiquitin and ribosomal polypeptides (as reviewed
by Kimura and Tanaka, 2010). Processing of these ubiquitin fusion proteins by
deubiquitinating

enzymes (DUBs) produces monomeric ubiquitin capable of

covalently modifying target proteins. Additionally, DUBs remove ubiquitin from

1

substrates, thus playing a dual role in the dynamic regulation of ubiquitin
modified proteins in the cell.
Contrary to ubiquitin, SUMO precursors are not expressed as fusion proteins,
however, they still require processing by SUMO-specific proteases (Ulps) that
render them capable of covalent conjugation to substrates . Three isoforms of
SUMO exist in mammals (SUM01, 2, and 3) and only one type of SUMO exists
in yeast (Smt3).

The conjugation of ubiquitin and SUMO to substrates
The energy dependent conjugation of ubiquitin or SUMO to a target is
orchestrated by an enzymatic cascade involving E1 activating, E2 conjugating
and E3 ligating enzymes, processes termed ubiquitylation or sumoylation,
respectively (reviewed by Kerscher et al., 2006; Xie et al., 2007) (Model 1).
The Ubl enzyme cascade generally employs target specificity through the E3
ligating enzymes, which harbor substrate binding sites (reviewed by Bergink and
Jentsch, 2009). Interestingly, a consensus motif for covalent SUMO modification
has been reported while a ubiquitylation motif remains to be described. SUMO is
attached to a substrate covalently at a consensus motif on the target. The SUMO
E2 conjugating enzyme, Ubc9, assists in the conjugation of SUMO by
recognizing this motif( iJjKXE : i|j is a hydrophobic amino acid, and X is any
amino acid).
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UBL Precursor
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DUB or ULPs
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Model 1. The ubiquitin and SUMO substrates conjugation cycle. Once a Ubl
(purple sphere) is conjugation competent, lysine side chains of a substrate
protein (orange sphere) and a carboxy-terminus attachment motif of the Ubl form
a covalent bond. The attachment of the Ubl imparts functional modifications to
the substrate. SUMO and ubiquitin can be attached to substrates as monomers
or multimers. Ubl chains formation results due to modification of specific lysines
within the Ubls themselves. The conjugation of a Ubl to it targets occurs in a
unidirectional nature as a result of varying relative affinities between the E1, E2
and E3 enzymes (blue, pink and yellow spheres) (reviewed by Kerscher et al.,
2006). The Ubls can then be dynamically removed by Ubl-specific proteases
(DUBs and Ulps).
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The consequences of ubiquitylation or sumoylation
Ubiquitylation or sumoylation in vivo usually result in different ends for a target
protein. The downstream effects of sumoylation on a target protein can result in
events like sequestration from a binding partner, the localization of a binding
partner to the modified target, or conformational change in the target protein
(reviewed by Geiss-Friedlander & Melchior, 2007 ). On the other hand, in the
majority of cases, ubiquitylation in vivo results in proteasomal destruction of the
target (as reviewed by Ulrich, 2005).
Several SUMO functions can be illustrated by two representative SUMOsubstrate interactions. The yeast polymerase processing factor PCNA is
sumoylated in vivo and this modification incurs two downstream effects. First, the
modification acts as a signal to recruit the DNA helicase Srs2. The recruitment of
Srs2 takes part in a pathway which allows error free DNA replication. Second, the
SUMO modification of PCNA prevents interaction with elements of the Rad51
mediated homologous recombination pathway, which are not desirable at sites of
DNA synthesis. Therefore, SUMO modification of PCNA recruits one binding
partner and deters the interaction with others (Papouli et al., 2005).
A second representative SUMO substrate is thymine DNA glycosylase (TDG).
TDG is an enzyme that removes mismatched thymine and uracil bases. In
performing its function TDG removes the unwanted bases and remains tightly
bound to the DNA. The modification of TDG with SUMO causes a conformational
change that releases the enzyme from the DNA ( Kerscher, 2007). Other SUMO
modified substrates and results of their modification can be seen in Table 1.
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Table 1. Examples of SUMO function
Protein

Description of
Function

SUMO’s Role

Reference

kB a

Sumoylation blocks
phosphorylation and
subsequent
ubiquitylation

Prevents degradation

Reviewed by
Ulrich, 2005

PCNA

Sumoylated to recruit
the SIM containing
helicase Srs2

Protein interaction

Papouli et al.,
2005

PML

SIMs and SUMO on
each PML protein act
as scaffold for
nuclear body
formation

Nuclear body formation

Reviewed by
Seeler and
Dejean, 2003

Smad4

Sumoylation of this
transcription factor
recruits the SIM
containing
transcriptional
repressor, Daxx

transcriptional
repression

Chang et al., 2005

Rad52

Sumoylation of
Rad52 negatively
affects its
recombination activity

Attenuation of activity

Sacher et al., 2006

Cdc3, Cdc11, Shs1

These septins
become briefly
sumoylated in Mphase

Function unknown

Johnson et al.,
2001
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As mentioned the majority of known ubiquitin substrates are destined for
proteasomal degradation. The 26S proteasome recognizes polyubiquitylated
proteins and degrades them into small peptides in order to allow for proper
protein quality control, transcriptional regulation and cell-cycle progression
(Hochstrasser, 2009). However, ubiquitin, like SUMO, has other functions that
can impart dynamic changes in the activity and localization of modified
substrates. A representative substrate for ubiquitin modification, the tumor
suppressor p53, illustrates the versatility of ubiquitin as a post-translational
modifier. p53 can be polyubiquitylated, in which case it is destined for
proteasomal destruction, or it can be monoubiquitylated which causes its export
from the nucleus and sequestration from its transcriptional targets (Boyd et al.,
2000; Geyer et al., 2000).

Crosstalk between SUMO and ubiquitin
Despite the fact that thousands of targets are known to be modified by
ubiquitin and SUMO, the details of the down stream effects of these
modifications are often unclear, especially in the case of SUMO. Elucidation of
these pathways becomes complicated for three main reasons. First, the transient
and dynamic nature of Ubl modification makes it difficult to track the effects of Ubl
modifications to their ends. Second, at any given time a very small percentage of
a target protein is in its Ubl modified state. Third, in recent years the cross-talk
between the SUMO and ubiquitin systems has proven to be very complex . Some
proteins, including PCNA and p53 mentioned above, are modified by both SUMO
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and ubiquitin (reviewed by Ulrich, 2005). The relationship between SUMO and
ubiquitin modification was originally thought to be antagonistic due to competition
for the same lysine residues on shared substrates. However, further research
revealed that Ubl modification cannot necessarily be understood at the level of
an individual substrate. SUMO and ubiquitin can compete for target lysines, but
they can also have sequential effects on a target. For example, SUMO or
ubiquitin conjugation may at one point in the cell cycle promote transcription of a
particular gene and at a different point suppress transcription. The overall effect
is based

on

the very temporal and cumulative effects underlying a specific

landscape of Ubl modifications in the pathway. The possibilities for SUMO and
ubiquitin modification become blurred even further when one considers elements
like possible branched ubiquitin chains and SUMO chains that become modified
with ubiquitin (reviewed by Bergink and Jentsch, 2009).
A good example of the cumulative effects of SUMO and ubiquitin is the NF-kB
pathway. NF-kB is a transcriptional activator that is sequestered in the cytosol.
An inhibitor called kB a binds NF-k B and maintains its cytosolic localization .
kB a is first phosphorylated by a kinase called IKK, following phosphorylation
ubiquitylation of kB a causes it to be degraded. Degradation of kB a allows
access of NF-kB into the nucleus. In an antagonistic role, sumoylation of kB a
prevents it ubiquitylation and subsequent degradation, thus preventing entrance
of NF-kB into the nucleus. Intriguingly, SUMO and ubiquitin cooperate to activate
NF-kB through the modification of a subunit of the IKK kinase called NEMO.
Genotoxic stress induces the SUMO modification of NEMO in the cytosol; at this
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point in time the IKK kinase is inactive. Sumoylation causes NEMO to be
imported into the nucleus where it is first phosphorylated and then ubiquitylated.
Addition of ubiquitin to NEMO causes it to leave the nucleus and join up with the
other subunits of IKK. While NEMO is ubiquitylated IKK is in its active state and
can promote the degradation of IkBo and the activation of NF-kB ( reviewed by
Ulrich, 2005).

Non-covalent interaction with SUMO and ubiquitin
Many proteins can recognize and interact with substrates of Ubl modification
in a non-covalent manner. Non-covalent interactors of SUMO and ubiquitin
contain SUMO-interacting motifs (SIMs) or ubiquitin binding domains,
respectively. In the case of ubiquitin, at least 20 different UBDs have been
described and this number continues to grow (as reviewed by Hicke et al., 2005).
There is no common structure that the various UBDs use to interact with
ubiquitin; however, distinct examples have shown that structures including single
or double helices, as well as (B-strands or loops are responsible for the ubiquitin
interaction (as reviewed by Hicke et al., 2005). Interestingly, there is a
commonality in the surface on ubiquitin that UBDs contact. This surface is a
hydrophobic patch of residues in ubiquitin that is centered around Ile44.
In the case of SUMO only one canonical SUMO-interacting motif (SIM) has
been characterized (Hochstrasser, 2009; Kerscher, 2007). Known SIM containing
proteins harbor a loose consensus motif (V/l-X-V/l-V/l) that forms a hydrophobic
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extension (Song et al., 2004). This extension of the SIM embeds in a groove
within SUMO that shares its hydrophobic properties.

Slx5/Slx8: A SUMO-targeted Ubiquitin Ligase
The Slx5/Slx8 complex is the founding member of a novel class of ubiquitin
E3 ligases, termed STUbLs (SUMO-targeted Ubiquitin ligases). The cooperative
crosstalk between the SUMO and ubiquitin systems has taken new directions
with the discovery of this unique subclass of E3 ligases. The discovery of
STUbLs has revealed a novel role for SUMO in proteolytic degradation. As a
heterodimer with Slx8, Slx5 is believed to aid in the targeting of sumoylated
proteins using its four bona fide SIMs. Then, Slx8 is believed to carry out the
sequential ubiquitin-ligase function of the complex through the activity of its RING
domain, a hallmark of ubiquitin E3 ligases. STUbLs have been suggested to play
roles in telomere maintenance, transcriptional regulation, DNA repair and protein
quality control among others (reviewed by Heideker et al., 2009; Wang and
Prelich, 2009).

The role of STUbls in genome stability
Slx5 and Slx8 were originally isolated from a synthetic lethal screen with the
DNA helicase Sgs1 which is required for genome stability (Mullen et al., 2001).
Since their identification in this initial screen, multiple lines of evidence suggest
that Slx5/Slx8 is required for genome integrity and proper DNA damage response
by controlling cellular levels of sumoylated proteins (Zhang et al., 2006; Uzunova
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et al., 2007; Xie et al., 2007). First, mutations in SLX5 and SLX8 cause elevated
rates of gross chromosomal rearrangements (GCRs) and spontaneous DNA
damage. Secondly, Slx5 and Slx8 play a critical role in limiting the significantly
greater levels of high-molecular weight SUMO-conjugates found in both single
and double knockout strains for the heterodimer. Additionally, Slx5 forms distinct
foci in the nuclei of live yeast cells, co-localizes with DNA repair foci, and
interacts with double stranded DNA breaks ( Nagai et al., 2008, Cook et al.,
2009 ). These foci are dependent upon the presence of SUMO, the ability of the
cells to synthesize poly-SUMO chains, and the presence of SIMs within the Slx5
protein (Cook et al., 2009). Slx5 may bind directly to chromatin by interacting with
sumoylated target proteins at sites of DNA repair. In fact, Slx5 has been shown to
co-localize with the DNA damage repair protein Rad52, a known SUMO target,
within sites of DNA repair, and Rad52 was identified as the first in vitro substrate
of the Slx5/Slx8 STUbL (Xie et al., 2007).

In vivo substrates of Slx5/Slx8 and RNF4
In vivo substrates of the Slx5/Slx8 complex include the transcriptional
regulator Mot1, which regulates the activities of TATA-binding protein, and the
transcription factors MATal and MATa2, which regulate information encoded at
the mating type locus in budding yeast (Wang and Prelich, 2009; Xie et al., 2010;
Nixon et al., 2010).
STUbLs, and specifically the Slx5/Slx8 complex, are conserved from yeast to
humans. The human ortholog of Slx5/Slx8, RNF4, has been shown to
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ubiquitylate and degrade the sumoylated oncogenic fusion protein PML-RARa in
acute promyelocytic leukaemia (APL) (Lallemand-Breitenbach et al., 2008). In
patients with APL, treatment with arsenic trioxide induces sumoylation of wildtype PML and the oncogenic fusion protein. In turn, RNF4 targets these
sumoylated PML proteins and tags them with ubiquitin. The ubiquitylated proteins
are recognized and degraded by the proteasome. Interestingly, and distinct from
the Slx5/Slx8 complex, substrate ubiquitylation by RNF4 requires
homodimerization of the conserved E3 RING domain ( Liew et al., 2011). Insights
into Slx5/Slx8 may shed light on RNF4 and its substrates.

Slx5/Slx8 and the SUMO pathway
Several lines of evidence suggest that the Slx5/Slx8 complex is connected to
the SUMO pathway. The first evidence came when Slx5 was identified in a twohybrid screen as having a strong interaction with Smt3, yeast SUMO ( Uetz et al.,
2000; Hannich et al., 2005). Further supporting this notion, Wang and colleagues
identified Slx5 and Slx8 as having synthetic lethality with several components of
the sumoylation machinery (Wang et al., 2006). Slx5 and Slx8 mutant strains
were synthetically lethal or synthetically sick with the majority of SUMO pathway
components in budding yeast including: the SUMO E1 (AOS1/UBA2), the SUMO
E2 (UBC9), the SUMO E3 (SIZ2) and SUMO (SMT3). Curiously, there was no
effect on slx5A and slx8A strains when the SUMO E3 Siz1 was mutated. This is
intriguing because Siz1, along with Siz2, is responsible for 90% of sumoylation in
budding yeast.
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Additionally, Slx5 was identified as a high-copy suppressor of a ulplts mutant
(Xie et al., 2007); at the nonpermissive temperature, the SUMO protease Ulp1 is
nonfunctional and cannot cleave SUMO from substrates nor process the SUMO
precursor into its conjugation competent form. The fact that Slx5 can rescue this
mutant provided further evidence for a link between Slx5/Slx8 and the
sumoylation pathway.

Siz1 and Siz2: SUMO E3 ligases
As mentioned above, the majority of sumoylation in budding yeast is executed
by two of three E3 ligases, Siz1 and Siz2. Siz1 and Siz2 belong to the Siz/PIAS
(protein inhibitor of activated STAT) family of SUMO E3 ligases which are found
in all eukaryotes (Reindle et al., 2006). Siz/PIAS family E3s contain an SP-RING
domain which is similar to the ubiquitin ligase RING domain (Hochstrasser,
2001). In addition to the SP-RING domain Siz/PIAS proteins contain a SAP
domain responsible for DNA binding (Reindle et al., 2006). Within yeast cells
there are several distinct types of sumoylated conjugates. The first of these is the
pool in which Siz1 is required for substrate sumoylation, including the nuclear
protein PCNA and the cytosolic septin proteins. The second pool requires Siz2
for modification, which includes several unidentified proteins. The third pool
requires both Siz1 and Siz2; there are many substrates in this group, most of
which have not yet been identified but includes Top2, topoisomerase II. Lastly,
the Net1 protein can be modified by any of the three known E3 ligases in budding
yeast (Reindle et al., 2006).
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While Siz2 is thought to play primarily a nuclear role in sumoylation, Siz1 is
dynamically shuttled between the nucleus and the cytoplasm. Siz1 localizes to
the bud-neck just before mitosis and is primarily responsible for the cytosolic
sumoylation of the septins Cdc3, Cdc11, and Shs1/Sep7 in yeast cells (Johnson
and Gupta, 2001; Takahashi et al., 2005). The karyopherin Kap95 is responsible
for importing Siz1, while Kap142/Msn5 exports Siz1 to the cytoplasm.

Septin sumoylation
The septins are one of the most interesting groups of sumoylated proteins in
the cell. The septin proteins belong to a family of GTPases and, despite being
the most sumoylated proteins in mitosis, the implications of septin sumoylation
are yet to be described.

The modification of yeast septins occurs prior to

anaphase and is terminated by the Ulp1 SUMO protease at cytokenesis
(Johnson and Blobel, 1999; Takahashi et al., 1999). In yeast the septins form a
ring composed of 10nm filaments which has two primary functions: 1) The
septins act as a scaffold for other protein-protein interactions at the bud-neck and
2) they prevent the diffusion of membrane proteins between the mother cell and
the daughter bud. Septins have been implicated in roles including; bud-site
selection, cell polarity, cytokenesis, and microtubule organization (Johnson and
Blobel, 1999; as reviewed by Spiliotis, 2010). Septins are absent in plants;
however, they are highly conserved from yeast to humans (reviewed by Spiliotis,
2010; reviewed by Takahashi et al., 2008). While yeast only express seven
septins, mammals express 30 septin protein isoforms produced by 14 genes
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(Spiliotis, 2010). Defects in septin proteins have been implicated in several
pathological conditions including tumorigenesis and Parkinson disease (as
reviewed by Barral and Kinoshita, 2008).

This study: a role for Slx5/Slx8 in cytosolic sumoylation
The Slx5/Slx8 heterodimer constitutes a SUMO-targeted Ubiquitin Ligase
(STUbL) with an important role in regulating the levels of sumoylated proteins.
This STUbL relies on SUMO-interacting motifs (SIMs) in Slx5 for substrate
targeting and a carboxy-terminal RING domain in Slx5 and Slx8 for substrate
ubiquitylation.

In budding yeast cells Slx5 and Slx8 reside in the nucleus, form

distinct foci, and can associate with double-stranded DNA (dsDNA) breaks. It is
also known that Slx5 and Slx8 have strong

genetic interactions with the

enzymes of the SUMO conjugation pathway and several in vivo targets of the
STUbL have been revealed. However, little is known about the precise functional
interactions of Slx5/Slx8 in the nuclei of living cells. The goal of this research was
to better characterize STUbL activity through a structure-function assay of
individual domains in the targeting subunit of the complex, Slx5. Here we present
our analysis of I) the domains involved in the subnuclear localization of Slx5; II)
the domains within Slx5 required for interaction with its known binding partners;
and III) a potential role for the Slx5/Slx8 STUbL in the regulation of protein
sumoylation through the interaction with and putative regulation of an important
SUMO pathway enzyme, Siz1.
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MATERIALS AND METHODS
Yeast strains. Media and Plasmids.
Yeast strains and plasmids used in this study are listed in the Appendix:
Supplementary Table 1. Yeast media preparation and manipulation of yeast cells
was performed as previously published (Guthrie and Fink, 1991). Yeast strains
were grown at 30°C unless otherwise noted. DNA fragments containing fulllength and truncations of Slx5 under control of its endogenous promotor were
amplified from yeast genomic DNA and placed in-frame with a carboxy-terminal
GFP tag in the CEN/LEU2 plasmid pAA3. All construct were sequence verified.
For two-hybrid constructs ORFs or truncations of the indicated genes were PCRamplified and homologously recombined into gapped pOAD and pOBD2 vectors
(Yeast Resource Center, WA). All constructs were sequence verified. For the in
vitro ubiquitylation and pulldown assays MBP-Slx5 and MBP-Slx8 were over
expressed from the pMALc-HT vector (A gift from Sean Prigge, JHSOM) in
bacterial cells containing a pRIL plasmid. Siz1 was over-expressed from a
plasmid attained from AddGene - pT-77-SIZ1 A440-His (Takahashi et al., 2005)
and the His6-Ubc4 plasmid was attained from (Boston Biochem). For the in vivo
pulldown assays GST-Slx5

was purchased from the Open Biosystems yeast

GST-tagged collection. The pRS424 Gal-Siz1 His/Flag plasmid was a gift from
Erica Johnson and the 9MYC-Siz1 strain was a gift from Helle Ulrich.
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Yeast Two-Hybrid Assays
The indicated Gal4-activation-domain (AD) fusion constructs and Gal4binding-domain fusion constructs were transformed into the AH109 (Clontech)
reporter strain. Interactions were scored on dropout media lacking adenine. Cells
were either struck onto the media or spotted and analyzed after three days of
growth.

Pulldown Assays. Affinity Purification, and Protein Extracts
Induction of protein over-expression with IPTG in bacteria - One colony of
BL21(DE3) or *R cells expressing the recombinant protein to be purified was
inoculated in 4 ml_ of LB broth containing the appropriate antibiotic and grown up
overnight by rotating at 37°C. This 4 mL culture was transferred to a flask
containing 200 mL SOC and grown up at 37°C to ODeoo 0.3-0.4. A 1 mL sample
of this uninduced culture was collected and centrifuged. After discarding the
supernatant, the cell pellet was resuspended in 60 pL of 1x LDS Sample Buffer
(Invitrogen) containing BME (40 pL/1 mL sample buffer). This sample was boiled
in a 110°C heat block for three minutes and then frozen in liquid nitrogen. This
was done a total of three times.
After adding 80 pL of 1 M IPTG to the remaining 203 mL of bacterial culture,
these cells were transferred to a 30°C shaker, where they were induced for 3.5 5 hours. Another 1 mL sample was collected as described above. To analyze
protein induction, whole-cell protein extracts from uninduced and induced cell
cultures were compared by running 10 pL of each 1 mL collection on a pre-cast
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NuPAGE Novex 4-12% Bis-Tris mini-gel (Invitrogen) for 55 minutes at 200 V in
MOPS Buffer (Invitrogen). These gels were rinsed in distilled water, stained in
either GelCode Blue (Pierce) or SimplyBlue Safe Stain (Invitrogen) for one hour,
and destained in distilled water for another hour. Gels were placed on wet
Whatman paper, covered with plastic wrap, and placed in a gel dryer for
approximately 45 minutes at 80°C. The remainder of the cell culture was
centrifuged at 4°C for 15 minutes at 5,000 RPM. After discarding the supernatant,
cell pellets were kept on ice and gently resuspended by pipetting in 4 mL of 1x
Halt Protease Inhibitor Cocktail (PI) (Thermo), diluted in 1x PBS. These 4 mL
cultures were then spun down into screw-cap tubes and frozen in liquid nitrogen.

Recombinant protein purification from bacteria - Frozen cell pellets of IPTGinduced BL21(DE3) or *R cells were resuspended in 800 pL 1x Halt Protease
Inhibitor Cocktail by pipetting. 1x PBS was then added to 2 mL. Cells were
sonicated three times using a Branson sonifier. Sonicated cells were then
centrifuged at 4 °C for 8 minutes at approximately 15,000 RPM. Protein extracts
were added to a 15 mL conical and diluted in 4 mL 1x PBS. Affinity columns
(Pierce) were assembled per the manufacturer’s instructions. His6-tagged
proteins (Ubc4 and Siz1A440) were purified on Talon beads (Clontech), and
MBP-tagged proteins (Slx5 and Slx8) were purified on amylose resin (New
England Biolabs). His6 proteins were eluted with elution buffer (His6: USB), and
MBP-tagged proteins were eluted with 100 mM maltose. Glycerol was added to
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15%. Elutions were then analyzed by gel staining as described previously.
Proteins were frozen in liquid nitrogen and stored at -80°C.

In vitro pulldown assay - MBP-Slx5, MBP-Slx8, and T7-Siz1 A440 were over
expressed in BL21 (DE3) or *R cells by IPTG induction as described above. Fifty
ODs of cells over-expressing either MBP-Slx5 or MBP-Slx8 were each combined
with 50 ODs of cells over-expressing T7-Siz1A440. Fifty ODs of cells over
expressing T7-Siz1 A440 were also collected. Whole-cell protein extracts were
then isolated and passed through a column containing amylose resin as
described above (Recombinant protein purification). Proteins bound to the
amylose resin were eluted with 1x LDS Sample Buffer (Invitrogen) and analyzed
by Western blot as described below.

In vivo yeast pulldown assays - For the GST-Slx5 pulldown of FLAG-Siz1 50
ml

yeast cultures were grown overnight in the appropriate selective media

containing 2% raffinose at 30°C. 25 ml of the overnight raffinose culture was
diluted into 150 ml of selective media containing 2% raffinose and 2% galactose
for induction of the plasmids containing GST-Slx5 and FLAG-Siz1. The 150 ml
culture was grown overnight at 30°C. 50 ml of the induced culture were harvested
by centrifugation (5,000 rpm, 10 min., 4°C). The cell pellet was washed in 1 ml
cold PBS and transfered to a new 2 ml micro-tube. The pellet was centrifuged
again as above and resuspended in 1 ml cold PBS containing protease inhibitor
(Halt Protease Inhibitor Single-Use Cocktail, EDTA-free. Thermo Scientific). Cells
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were lysed with an Omni Bead-ruptor 24 (Omni Inc.) for 2 pulses, 20s/pulse. The
lysate was cleared by centrifugation (15, 0000 rpm, 8 min., 4°C). 750

/j \

of the

supernatant was transfered to a new tube and 250 /yl of 1x PBS+ 1X Protease
Inhibitor (Halt Protease Inhibitor Single-Use Cocktail, EDTA-free. Thermo
Scientific) was added. The supernatant was cleared again as above. 2X sample
buffer was added to a whole cell sample (Invitrogen NUPAGE Sample Buffer)
and the sample was boiled (3 min. 110°C). The cleared lysate was added to 60 fj\
of PBS-washed glutathione agarose and nutated (1 h, 4°C). The beads were
washed 4 times with 1mL 1X PBS and samples were eluted using 75 /7l of 1X
sample buffer. The samples were boiled at 110°C for 1 min. 10

/j \

of the whole

sample and 25 fj\ of the elutions were seperated on a Bis/Tris protein gel and
analyzed by Western blot as described below.
For the MYC-Siz1 pulldown of Slx5(1-310)-GFP 5 ml cultures in the
appropriate selective media containing 2% dextrose were grown overnight at
30°C. The 5 ml cultures were diluted to OD6oo= .3 and grown at 30°C until the
cultures were logarithmically growing. Nocodazole was added to 15 fjg/ml and
the cells were grown at 25°C for 3 hr to arrest the cells at G2/M of the cell cycle.
50 OD’s of each sample were harvested by centrifugation (5,000 rpm, 10 min.,
4°C). The pellets were washed with 1 ml cold 1X PBS and transfered to a new
tube. The pellets were centrifuged again as above and resuspended in lysis
buffer (1X PBS, 5mM EDTA, 0.5% Triton X-100, 2X Protease Inhibitor (Halt
Protease Inhibitor Single-Use Cocktail, EDTA-free. Thermo Scientific), and 25mM
NEM.). The samples were pulsed twice, 20s/pulse, on the Omni Bead-ruptor 24
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(Omni Inc.). The lysates were cleared by centrifugation (15,000 rpm, 8 min., 4°C).
750 p\ of the supernatant was transfered to a new tube and 250 p\ lysis buffer
was added. The samples were cleared again as above and 20 p\ whole-cell
samples were saved. 780 p\ of the cleared samples were used for the pulldown
assay according to the instructions for the ProFoundTM c-Myc Tag IP/Co-IP Kit
(Thermo Scientific). 50 //I of 2X non-reducing sample buffer (provided in the kit)
was used to elute the beads. 20 p\ of the elute sample and 15 p\ of the whole-cell
samples were analyzed by Western blot as described below.

TCA yeast protein analysis of Cdc3-YFP - Cells were grown overnight in the
appropriate selective media containing 2% dextrose. The following day the
cultures were diluted into the same media to OD600= .3. Cells were incubated at
30°C until the cultures reached logorithmic growth. Nocodazole was added to the
cultures to 15 //g/ml and the cultures were incubated at 30°C for 2.5 hr. For the
Smt3-FLAG shift assay, 5 OD’s worth of each sample were harvested. In the
case of the cycloheximide-chase assay the cultures were treated with
cycloheximide (1mg per sample) and cells were harvested at the time points
indicated in Figure 5. Each sample was about 2.5 OD’s worth of cells. The
harvested cells were resuspended in 20% TCA

and tranfered to a new

microcentrifuge tube. The samples were spun down again and resuspended in
400 p\ of 20%TCA. 200/71 of glass beads (Sigma G8772-500g) were added and
the samples were shaken at 4°C for 4 min. The supernatant was transfered to a
new tube and centrifuged. 800 p\ of 2% TCA was added to the pellets. The
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samples were centrifuged again and the supernatant was removed. The samples
were resuspended in 200

>l/I

of TCA-sample buffer (15% glycerol, 80mM Tris

base, 3.5% SDS, Bromophenol Blue, and BME [40 /vl/ml]). The samples were
boiled at 110°C for 3 min., and analyzed by Western blot as described below.

In vitro Ubiquitylation Reactions. Recombinant Proteins and Anti-Bodies
In vitro ubiquitylation assay - Sizing and quantitation of enzymes and
substrates used in our in vitro ubiquitylation assays were performed with a
Protein 230 kit on the Agilent 2100 Bioanalyzer according to the manufacturer’s
instructions. 10x ubiquitylation buffer, E1 enzyme (Uba1), ATP, and 20x ubiquitin
were provided in a commercial ubiquitylation kit (Enzo). Ubiquitylation buffer, IPP
(100 U/ml), DTT (50 pM), E1 (Uba1), E2 (Ubc4), and E3 enzyme (Slx5-Slx8)
were combined with purified substrate protein (T7-Siz1 A440) and ubiquitin.
Reactions totaled 27 pL and were incubated in a 30°C heat block for three hours.
Reactions were stopped by adding an equal volume of SUTEB sample buffer
(0.01% bromophenol blue, 10 mM EDTA, 1% SDS, 50 mM Tris at pH 6.8, 8 M
Urea) containing DTT (5 pL of 1 M DTT/1 mL SUTEB sample buffer). Protein
products were boiled in a 65°C heat block for ten minutes, analyzed by Western
blot as described below, frozen in liquid nitrogen, and stored at -80°C.

Western blot - Proteins were separated on a pre-cast NuPAGE Novex 4-12%
Bis-Tris gel for 55 minutes at 200 V in 1x MOPS buffer. Proteins were then
transferred to a polyvinylidene difluorine (PVDF) membrane (Millipore) by semi
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dry transfer in semi-dry transfer buffer (192 mM glycine, 250 mM Tris Acetate at
pH 8.8, 20% methanol) for 30 minutes at 19 V. The blot was blocked in TBS (150
mM NaCI, 50 mM Tris-HCI at pH 7.4) containing 4% milk for an hour and then in
4% milk containing primary antibody overnight. a-Smt3R11B6 (Hochstrasser Lab,
Yale), a-GST (Abeam), a-avidin-HRP (Pierce), a-T7 (Novagen), a-SUM02
(Michael J. Matunis, JHSOM), and a-MBP (New England Biolabs) primary
antibodies were used, all at a concentration of 1:10,000. a-GFP JL-8 (Clontech)
was used at 1:4000. After three, five-minute washes in large volumes of TBS
containing TWEEN20 (1 mLTWEEN20/1 LTBS), blots were incubated in a-rabbit
HRP (Abeam) or a-mouse HRP (GE) for 90 minutes and then washed again in
large volumes of TBST three times for five minutes each. Chemiluminescent
substrate (Millipore) was added to the blot, which was then wrapped in Saran
wrap and exposed to film.

Fluorescent Microscopy
Unless otherwise noted, cells we grown in rich media, arrested at G2/M using
nocodazole (15jLyg/ml/3h/30°C), washed in ddH 20 and harvested by
centrifugation. Images of live cells were collected using a Zeiss Axioskop fitted
with a Retiga SRV camera (Q-imaging), i-Vision software (BioVision
Technologies), and a Uniblitz shutter assembly (Rochester, NY). Pertinent filter
sets for the above applications include CZ909 (GFP), XF114-2 (CFP), and
XF104-2 (YFP) (Chroma Technology Group). Images were normalized relative to
one another using the batch convert function of i-Vision software before
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quantification and pseudo-colored and adjusted using Adobe Photoshop software
(Adobe Systems Inc.)
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RESULTS
Targeting of Slx5 depends on a nuclear-localization domain and SIMs
Slx5 is the targeting subunit of the heterodimeric Slx5/Slx8 STUbL complex in
budding yeast (Xie et al., 2007; Ununova et al.,2007). The Slx5 protein contains
at least four SIMs (amino acids 24-158) and a carboxy-terminal RING domains
(amino acids 490-620) (Figure 1A) (Mullen et al., 2001, Uzunova et al., 2007, Xie
et al., 2007, Cook et al., 2009, Xie et al., 2010). We previously reported that SIMs
in Slx5 are required for the formation of nuclear foci while the RING domain is
required for activity of the Slx5/Slx8 STUbL (Cook et al., 2009, Xie et al., 2007).
Considering the important role of STUBLs in DNA repair and the
prevention of gross chromosomal rearrangements, we asked if particular
domains in Slx5 are required for nuclear localization. Therefore, we determined
the sub-cellular localization of six carboxy-terminal Slx5 truncations (C1-C6)
(Figure 1B). These Slx5 truncations differed by about 100 amino-acids in length,
with one exception, Slx5 construct C6 was 50 amino-acids (aa) in length and
contained only SIM1 of Slx5 (Figure 1A). We reasoned that these truncations
would allow us to observe where particular fragments of Slx5 localized in the cell
and we would be able to determine the domain responsible for nuclear
localization.
All GFP-tagged Slx5 truncations and the full-length Slx5-GFP control (Cook et
al., 2009), were expressed under control of the native Slx5 promotor.
Representative images of cells expressing GFP-tagged Slx5 truncations were
recorded at early log-phase (Figure 1B). Image analysis of our carboxy-terminal
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Slx5-GFP truncation revealed that the absence of the Slx5 RING domain (aa
490-620) does not affect nuclear localization and the formation of nuclear foci.
Interestingly, a Slx5-GFP truncation consisting only of the amino-terminal half of
Slx5 (C3: 1-310), still showed a strong nuclear signal. This nuclear localization
was abruptly altered in a slightly shorter Slx5-GFP truncation (C4: Slx5GFP(1-207)). Slx5-GFP(1-207) appeared to reside both in the cytoplasm and in
the nucleus. It is unlikely that the Slx5-GFP(1-207) fusion protein simply leaked
from the nucleus because this GFP-tagged Slx5 truncation is larger (~57kDa)
than the defined molecular weight for passive nuclear diffusion. As expected,
constructs that were even smaller than Slx5-GFP(1-207), C5(1-104) and
C6(1-50), also failed to be enriched in the nucleus.

Therefore, the domain

encompassing amino acid 207-310, may serve as a crucial nuclear localization
and/or retention domain of Slx5.
We further investigated the functional relevance of the Slx5(207-310) domain.
Fusion of Slx5(207-310) to GFP revealed that this domain, when expressed in
wildtype yeast cells, is necessary and sufficient for nuclear localization.
Slx5(207-310)-GFP shows a diffuse nuclear enrichment with some residual
cytosolic staining (Figure 1B). We also deleted amino acids 207-310 from fulllength Slx5-GFP. This construct, Slx5(A207-310), failed to enter the nucleus and
aggregated with a perinuclear distribution pattern (data not shown). In summary,
our data suggests that Slx5 contains a distinct domain required for nuclear
localization.
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Figure 1. Identification of a Nuclear Localization Domain in Slx5. A) Depicted
are six carboxy-terminal deletions (C1-C6) of Slx5. The length of each truncation
construct is indicated by the scale above with full-length Slx5 being 620 aminoacids in length. Also indicated are SIMs and the RING domain of the full length
(WT) Slx5 protein. B) Localization of each Slx5 truncation (C1-C6) (yellow arrow
indicates bud-neck localization), the full-length Slx5 protein (WT), and the nuclear
localization domain fragment (red arrow), amino acids 207-310, are shown.
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A truncation of Slx5 is enriched at the bud-neck of dividing cells.
Careful analysis of the carboxy-terminal truncations of Slx5 (Figure 1B)
revealed that Slx5(C4: 1-207) mislocalized not only to the cytoplasm but also
exhibited a strong staining of the bud-neck, reminiscent of the septin ring (Figure
1B). Septins, including Cdc3, Cdc10, Cdc11, Cdc12 and Shs1/Sep7, form a ring
like 10-nanometer filament structure at the junction between mother and
daughter cell of yeast (Johnson and Blobel, 1999).

These proteins play an

important role in mitosis and cytokinesis and are involved in processes including
microtubule capture, chitin deposition, and septum formation. Additionally,
septins are the most highly sumoylated protein at G2/M of the cell cycle (Kusch
et al., 2002).
In order to test if Slx5(1-207) co-localized with individual septins we
chromosomally-tagged CDC3 with the gene encoding the yellow fluorescent
protein (YFP). This CDC3-YFP strain was then transformed with a plasmid
carrying SLX5(1-207) fused to the gene encoding the cyan fluorescent protein
(CFP).

Live imaging of G2/M arrested cells revealed that both Cdc3-YFP and

Slx5(1-207)-CFP fusion proteins were expressed and co-localized to septin rings
in the majority (-80%) of large budded cells (Figure 2A).

G2/M arrested cells

contain only one septin ring and consistent with this observation Cdc3 and Slx5
staining was limited to this structure. In logarithmically growing cells co
localization of Slx5(1-207) and Cdc3-YFP to one or two septin rings was
observed (-20%). However, septin-localization of Slx5(1-207) was limited to
large-budded cells in mitosis.
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Figure 2. SLX5(1-207) localizes to the septin ring in a SIM dependent and
SUMO chain independent manner. A) Cells expressing Cdc3-YFP were
transformed with SLX5(1-207)-CFP, then arrested with nocodazole and benomyl
for 150 minutes at 25°C before microscopy. The majority of cells displayed co
localization of SLX5(1-207)-CFP with the septin ring. B) The septin ring
localization (arrows) of Slx5(1-207) depends on SIM1 and 2 but not SUMO
chains.
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Since Slx5 interacts strongly with SUMO and SUMO chains (Xie et al., 2007)
we reasoned that the mislocalization of Slx5-(1-207) to septins may also depend
on SUMO.

Several septins (Cdc3, Cdc11, and Shs1) are highly sumoylated in

the G2/M phase of the cell cycle and may provide binding sites for the cytosolic
Slx5 truncation. Therefore, we examined the ability of Slx5-(1-207) with a SIMA/B
mutations (25-AAA-27 and 93-ATAA-96) to localize to septins.

We previously

showed that both SIM1 and 2 play an important role in the formation of Slx5
nuclear foci and SUMO binding (Xie et al., 2007, Cook 2009). The Slx5-(1-207)
SIMA/B mutant (and a control plasmid with intact SIMs) were transformed into a
wildtype strain and arrested cells were examined. Notably, enrichment of Slx5(1-207) SIMA/B to septins was greatly reduced but not eliminated (Figure 2B).
We made a similar observation when Slx5-(1-207) was expressed in a strain that
is unable to form polySUMO chains (smt3-R11,15,19) (Bylebyl et al., 2003). Slx5(1-207) septin mislocalization was greatly reduced but not eliminated in smt3R11,15,19 cells (Figure 2B).
In summary, these data suggest that the bud-neck mislocalization of the
Slx5(1-207) truncation depends on cell cycle-specific septin sumoylation and that
SIMs in Slx5 are necessary and sufficient for targeting of sumoylated proteins.
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Figure 3. A) Slx5 uses distinct domains to interact with Slx5, Slx8, yeast SUMO (Smt3), and
Siz1. Left: Depicted are six carboxy-terminal deletions (C1-C6) and six amino-terminal deletions
(N1-N6) of Slx5. The length of each truncation constructs is indicated by the scale above with
full-length Slx5 being 620 amino-acids in length. Also indicated are SIMs and the RING domain
of the full length (WT) Slx5 protein. Bottom right: Duplicate spots of yeast cell colony patches
indicate two-hybrid interactions of Slx5 with full length Slx5, Slx8, Smt3 (yeast SUMO), and Siz1
Top right: Interactions of Slx5, Slx8, SMT3, and Siz1 with individual Slx5 truncations (aminoterminal (N): N1-N6 and carboxy-terminal (C): C1-C6) correspond to the Slx5 truncations
displayed on the left. B) Summary of domains identified in Slx5. Rendering of full length Slx5.
Indicated are the location of SIMs, RING domain, NLS, yeast SUMO & Siz1 interacting domains,
and the regions required for Slx5 and Slx8 interaction (black bars). The length of each domain
and feature is indicated by the scale above (amino acid 1-620) with full-length Slx5.
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The STUbL subunit Slx5 has three distinct and separate protein interaction
domains for the interaction with Six8, Six5, and SUMO.
The results obtained in our localization studies (Figure 1B) raised the
possibility that individual domains of Slx5 may be employed for functional
association with different types of interacting proteins. For example, sumoylated
substrates, other STUbL subunits, or nuclear transport factors may associate
with a particular domain within Slx5.
To test this hypothesis, we initially focused on the interaction of Slx5 with two
known interactors, SUMO and Slx8 (Xie et al., 2007; Li et al., 2007). Specifically,
we delineated the interaction domains of Slx5 using a collection of six aminoterminal (N1-N6) and six carboxy-terminal Slx5 bait truncations (C1-C6) (Figure
3A, Left). Full-length or truncated Slx5 bait constructs (Gal4-BD fusion) were co
transformed with the appropriate prey constructs (Gal4-AD fusion of Slx8 or
SUMO) into a two-hybrid reporter strain (AH109).

Bait/Prey interactions were

scored as growth of double-transformants on growth media lacking adenine
(Figure 3A, Right). Our data confirmed that full-length Slx5 interacts with SUMO
and Slx8 (Figure 3A, Bottom Right).

Furthermore, we unexpectedly found that

full-length Slx5 can also interact with other Slx5 proteins, raising the possibility
that this STUbL subunit, at least sometimes, may exist as a homodimer.
Analysis of the Slx5 bait truncations reveals that at least one SIM (SIM1) is
required for interaction with yeast SUMO (see Figure 3: C6 with SUMO).

In

contrast, the interaction of Slx5 bait with other Slx5 prey proteins was
independent of SIM1,2,3 and 4 and dependent on the domain between amino
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acid 207 and 310 (see Figure 3A: N4 and C3 with SLX5). Interestingly, Slx5
(207-310) was the same domain required for nuclear localization of Slx5 (Fig 1B,
Red Arrow). One possible explanation of this finding is that homodimerization is
required for nuclear import or nuclear retention of Slx5. Another possible role
might be that homodimerization of Slx5 may also prevent the premature
association of this STUbL subunit with sumoylated proteins in the cytosol.
The interaction of Slx5 with Slx8 was more complex.

One Slx5 truncation

(C1), retaining only two cysteine residues (Cys494 and Cys497) of the RING
domain, showed a reproducible though weaker interaction with Slx8.
Surprisingly, none of the Slx5 amino-terminal deletions (N1-6) scored positive in
our interaction assay with Slx8. This suggests that at least 50 residues of the
amino-terminus, including SIM 1, but not the entire RING domain of Slx5 is
required for interaction with Slx8.
To further investigate how Slx5 interacts with Slx8 we employed a full-length
Slx5 bait construct lacking both SIM1 and SIM2 (sim-A/B Slx5) (Xie et al., 2007).
Full-length Slx8 prey and sim-A/B Slx5 bait were co-transformed into the twohybrid assay strain. As a control both constructs were also tested against SMT3
and SLX5 constructs.

In accordance with the above data, the sim-A/B Slx5

mutant interacted strongly with Slx5, failed to interact with Smt3, and was greatly
reduced in its interaction with Slx8 (Supplementary Figure 1A). Therefore, both
SIMs 1 and 2 and the RING domain of Slx5 may be important for the interaction
with Slx8. In summary, our two-hybrid fine-structure mapping defines three

32

distinct Slx5 domains required for interaction with yeast SUMO (aa 1-207), Slx5
(aa 207-310), and Slx8 (aa 1-50 and 490-620) (Figure 3B).

The STUbL subunit Slx5 forms a complex with the SUMO ligase Siz1
Because Slx5(1-207) localized to septins in a SUMO-dependent manner, we
decided to test its interaction with potential sumoylated substrate proteins at the
bud-neck. Despite its enrichment at the septin ring, Slx5(1-207) failed to interact
with the septins Cdc3 and Cdc11 (data not shown).

However, to our surprise,

Slx5 interacted in a two-hybrid assay with a known septin-interacting protein, the
SUMO E3 ligase Siz1 (Figure 2, Bottom Right). Siz1 resides in the nucleus but
becomes enriched on the septin ring during the G2/M phase of the cell cycle to
sumoylate septin proteins.
We decided to investigate which domains of Slx5 were required for the
interaction with Siz1. Using our panel of Slx5 baits we found that the interaction
of Siz1 requires at least one SIM (SIM1) for interaction with Slx5 (Figure 2B).
The observed interaction closely mirrors the pattern we observed for interaction
between Slx5 and SUMO. One possible reason for this finding is that the
interaction of Slx5 with Siz1 may depend on SUMO and possibly sumoylation of
Siz1.

Indeed, when we tested the interaction of Siz1 with the Slx5 SIM A/B

mutant, the interaction was no longer observed (Supplementary Figure 1B.)
To confirm our finding of the Slx5*Siz1 interaction we tested if both proteins
could interact in vivo. Briefly, we constructed a yeast strain in which both GST
epitope-tagged Slx5 and FLAG epitope-tagged Siz1 were expressed under
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control of the strong inducible Gal promotor (Johnson and Gupta, 2001).

From

lysates of this strain, GST-tagged Slx5 was affinity purified and co-purifying Siz1
was detected after immunoblotting with anti-FLAG antibodies (Figure 4B).
Additionally, we analyzed a yeast strain which expressed both Slx5(1-207)-GFP
plasmid at centromeric levels and chromosomally integrated Myc-tagged Siz1
(Parker et al., 2008).

From lysates of this strain, Myc-tagged Siz1 was affinity

purified and co-purifying Slx5(1-207)-GFP was detected after immuno-blotting
with an anti GFP antibodies (Figure 4A). In summary, we conclude that the
SUMO ligase Siz1 can form a complex with the STUbL targeting subunit Slx5 in
yeast cell.
Since the amounts of Siz1 that co-purified with Slx5 from yeast cell extracts
were limited we also purified both proteins and tested their interaction in vitro.
Specifically, we probed the ability of recombinant maltose-binding protein (MBP)
fusions of Slx5 and Slx8 to interact with T7-epitope-tagged Siz1(A440).
Siz1(A440) lacks the carboxy-terminal 439 amino acids but retains its SUMO
ligase activity (Takahashi, 2005). Specifically, we tested the ability of Siz1(A440)
to copurify with Slx5 and Slx8 bound to amylose/agarose beads.

In this assay

Siz1(A440) was specifically eluted with purified Slx5 and Slx8 (Figure 4C).
Importantly, in the absence of Slx5 and Slx8, Siz1(A440) failed to bind to
amylose/agarose beads. It was noted that the Siz1(A440) construct was not
sumoylated in this assay, yet our data suggest that Siz1 may be able to interact
with both subunits of the Slx5/Slx8 STUbL.
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Figure 4. The STUbL subunit Slx5 forms a complex with the SUMO ligase
Siz1. A) Slx5 and Siz1 interact in in vivo pulldown assays. Whole-cell
extracts of yeast cells expressing both Slx5(1-207)-GFP at CEN plasmid levels
and chromosomally integrated Myc-tagged Siz1 (Parker et al., 2008) were
prepared. From lysates of this strain, Myc-tagged Siz1 was affinity purified and
co-purifying Slx5(1-207)-GFP was detected after immuno-blotting with an anti
GFP antibody. B) Whole-cell extracts from yeast expressing Flag-tagged Siz1
and GST-tagged Slx5 were passed though a column containing glutothione resin.
The elute was washed and run on a 4%-12% Bis-tris gel with the WCE. The gel
was analyzed by Western Blotting with anti-GST and anti- FLAG antibodies. C)
Slx5 and Slx8 interact with Siz1 in an in vitro pulldown assay. Whole-cell
extracts from bacterial cell cultures containing overexpressed MBP-Slx5 and
Siz1A440; MBP-Slx8 and Siz1A440; and Siz1A440 were passed through a
column containing amylose resin. Inputs and eluates were run on a 4%-12% BisTris gels for either staining with SimplyBlue SafeStain or immunoblotting with an
anti-T7 antibody. Figure 4C by Brooke Matson.

SixS modulates the Siz1-mediated sumoylation o f septins.
Our finding that Slx5 and Siz1 can form a complex in yeast cells led us to
investigate how these proteins functionally interact with each other in the cell.
Since Siz1 sumoylates septins at the G2/M phase of the cell cycle we sought to
determine the effect of Slx5 on this process. Therefore, we examined the in vivo
sumoylation of the septin Cdc3 in an SLX5 deletion strain (slx5A). For our
experiments we used wildtype or slx5A cells expressing the septin Cdc3 fused to
the yellow fluorescent protein (CDC3-YFP). These cells were either arrested in
G2/M. CDC3-YFP was detected in protein extracts of arrested cells after western
blotting.

In logarithmically growing cells Cdc3-YFP was detected as a single

band (data not shown). After G2/M arrest, however, Cdc3-YFP showed several
clearly visible sumoylated adducts in wildtype cells (Figure 5). We confirmed the
identity of these bands as sumoylated Cdc3 by over-expression of FLAG-tagged
SUMO (Figure 5B). Unexpectedly, the sumoylation of Cdc3 in six5A cells, but not
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wildtype cells, was greatly reduced during G2/M arrest.

This finding suggests

that the ability of Siz1 to sumoylate septins was altered in the SLX5 mutant.
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Figure 5. The absence of Slx5 leads to decreased sumoylation of septin
proteins. A) Shown here are the results of a cycloheximide-chase assay of yeast
cells expressing the YFP-tagged septin protein Cdc3 in WT and s/x5A strains.
Yeast cell samples were harvested at the time points indicated after the addition
of cycloheximide. Protein extracts were prepared using TCA and analyzed by
Western blot (WB) with anti-GFP antibody. B) Expression of FLAG-tagged Smt3
reveals a shift in the high-molecular weight modification of Cdc3, thus indicating
the modification is SUMO. Western blots were probed with anti-PGK antibody as
a control to demonstrate equal protein loading.
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Several other mutants effect the sumoylation of septins including those
lacking SIZ1, MSN1, a transport factor implicated in Siz1 export from the
nucleus, and SLX8. Cdc3 sumoylation after G2/M arrest was dramatically
reduced in the sizIA, msn5A and slx8A strains (EUROSCARF, Mata collection).
The dramatic reduction in Cdc3 sumoylation in slx8A cells is consistent with a
role for Slx5 in Siz1-mediated Cdc3 sumoylation (Figure 6). These analyses
revealed that absence of the Slx5/Slx8 STUbL may affect either the nuclear
export of Siz1 or its ability to sumoylate Cdc3.

Cdc3-YFP (Smt3)'
Cdc3-YFP
WB: a-GFP

Figure 6. Cdc3 sumoylation is reduced in slx5A, slx8A s iz IA and msn5A
strains. Protein extracts were prepared using TCA from yeast cells expressing
the YFP-tagged septin protein Cdc3 in WT and mutant strains. The proteins were
analyzed by Western blot (WB) with anti-GFP antibody.
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Siz1 is an in vitro ubiqitylation substrate of Slx5/Slx8
The evidence presented above suggests that Siz1 forms a complex with Slx5.
Therefore, we tested Siz1 as a candidate substrate for the Slx5/Slx8 STUbL. For
our in vitro ubiquitylation assays we purified the Siz1A440 truncation, shown
above to interact with Slx5 and Slx8.

Recombinant Siz1A440 was found to be

ubiquitylated in a Slx5/Slx8 dependent fashion (Figure 7). Addition of an aminoterminal SUMO moiety to Siz1A440, forming SUMO-Siz1 A440, did not
dramatically stimulate the ubiquitylation of this fusion protein. It has been shown
that SUMO enhances the ubiquitylation of STUbL targets.

However, at least in

vitro, SUMO modification does not appear to be an absolute requirement for
specific Slx5/Slx8 mediated ubiquitylation (Xie et al., 2010). Another interesting
observation is that Siz1 is robustly ubiquitylated by Slx5/Slx8, but only with 2 or 3
ubiquitins. Therefore, Siz1 A440 is either modified with short ubiquitin chains or
becomes mono-ubiquitylation at multiple lysines. The monoubiquitylation of other
proteins has been implicated in intracellular trafficking including nuclear export.
Therefore, ubiquitylation of Siz1 by Slx5/Slx8 may not be a signal for proteasome
mediated degradation.
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Figure 7. The Slx5/Slx8 STUbL complex ubiquitylates the SUMO-ligating
enzyme Siz1 in an in vitro ubiquitylation assay. In vitro ubiquitylation
reactions were analyzed by Western blot and probed with anti-T7 antibody to
detect the T7-tagged Siz1A440 truncation. The high molecular weight smear in
the ALL lane indicates ubiquitylation of Siz1. Figure 7 by Brooke Matson.
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Absence of Slx5 reduces the localization of Siz1 to the bud-neck.
Sumoylation of the septin Cdc3 during mitosis requires the Msn1-mediated
nuclear export of Siz1 (see above and Makhnevych et al., 2007). Since deletions
of MSN1, SLX5, and SLX8 share similar Cdc3 sumoylation defects we
hypothesized that Slx5 and Slx8 may also modulate the nuclear export of Siz1.
Therefore, we observed the enrichment of Siz1-GFP at the bud-neck of cells
arrested in mitosis.

Briefly, wildtype and slx5A cells were arrested with

nocodazole and images of Siz1-GFP accumulation at the bud-neck were
recorded using a fluorescent microcope. As expected, Siz1-GFP in wildtype cells
showed a distinct bud-neck staining pattern after nocodazole arrest (Figure 8).
The maximum pixel intensity of the Siz1-GFP at the bud-neck was measured for
wildtype and slx5A cells using i-Vision software and a two-way ANOVA revealed
that the enrichment of Siz1-GFP at the bud neck was significantly reduced in
slx5A cells (see Figure 8 and Makhenavych et al., 2007). The lack of Siz1-GFP
accumulation at the bud-neck was not caused by a delayed G2/M growth arrest,
as all cells analyzed displayed a large-budded arrest phenotype with a single
nucleus at the bud neck. These data suggest that, at least in part, reduced levels
of bud-neck associated Siz1 may be responsible for the observed Cdc3
sumoylation defect in slx5A cells.
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Figure 8. Reduced Siz1 localization to the bud-neck in slx5A strains. A)
Illustrated here are representative images of the WT and slx5A strains expressing
Siz1-GFP. Logorithmically growing cells (25°C) were arrested with Nocodozole at
G2/M (25°C) prior to microscopy. The strains were generated by a cross between
a SLX5::KAN strain and a strain chromosomally tagged with Siz1-GFP (open
biosystems). Diploids were sporulated then dissected and three tetrads were
analyzed. B) The maximum pixel intensity at the bud-neck of the arrested cells
were normalized relative to one another (see methods), measured with iVision
software and the average maximum pixel intensity of the cell populations were
plotted for comparison. A two-way ANOVA was run for all of the tetrad data and
indicated the difference in WT and slx5A strains is significant with a P-value of
less than .0001 and an F-value of 223.21. The standard error of the data was
4.22, represented by the error bars in each column. The sample size for each
strain of tetrad 1 was n=68, tetrad 2 n=50, tetrad 3 n=50.

The Siz1-Slx5 interaction is conserved
In order to test if the interaction between Slx5 and Siz1 was conserved from
yeast to humans full-length RNF4 (human Slx5 ortholog) was cloned into the
yeast two-hybrid bait construct (Gal4-BD fusion) and was co-transformed with a
PIAS1 (human Siz1 ortholog) prey construct (Gal4-AD fusion of Slx8 or SUMO)
into a two-hybrid reporter strain (AH109). Intriguingly, the proteins interacted and
grew on media lacking adenine, suggesting that the interaction is conserved
(Figure 9).
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Figure 9. The Siz1-Slx5 interaction is conserved. Two-hybrid analysis
revealed that Slx5 and a RING mutant of its ortholog, RNF4, interact with PIAS1.
These interactions may indicate that the crosstalk of ubiquitin and SUMO ligases
may be conserved from yeast to humans. Spotting on media lacking tryptophan
and leucine indicated that the yeast strains contained both the Bait (BD) and
Prey (AD) plasmids. Growth on media lacking adenine indicated a protein
interaction. YOK1221 is a yeast strain used as a positive control. White dashes
indicate Bait/Prey combinations that were not tested.
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DISCUSSION
Our structure function analysis of Slx5 has led to several new insights into the
nuclear localization, pertinent domains, and activity of the Slx5/Slx8 STUbL
complex.
Analysis of GFP and two-hybrid truncation panels suggest that a nuclear
localization or nuclear retention domain resides between amino acids 207 and
310 of Slx5. The same region of the protein, amino acids 207-310, is responsible
for Slx5*Slx5 two-hybrid interaction, implicating a putative role for dimerization in
the nuclear-cytosolic shuttling of Slx5.
New interaction domains were also characterized within Slx5 for interaction
with Slx8 and the SUMO E3 ligase Siz1. The Slx5*Siz1 interaction has not been
previously reported. The conserved nature of this interaction is demonstrated by
the two-hybrid interaction of RNF4 and PIAS1, the orthologs of Slx5 and Siz1,
respectively.
Subsequently, we show that Siz1 not only forms a complex with Slx5, but that
it is also an in vitro target for ubquitylation by the Slx5/Slx8 STUbL. Curiously, in
the absence of Slx5 there is decreased sumoylation of the bud-neck septin
proteins at G2/M of the cell cycle, and an intriguing decrease in the level of Siz1
(responsible for sumoylation of the septins) at the bud-neck during G2/M.
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What are the protein interaction domains of Six5?
The present study reveals three novel protein interaction domains in Slx5
termed 1) a SUMO/substrate interaction domain, 2) an Slx8 binding domain and
3) a nuclear localization/homodimerization domain.
Identification of the SU MO/substrate interaction domain of Slx5 is based on
the interactions of our two-hybrid panel constructs with SUMO and Siz1.
Interaction of Slx5 with SUMO was dependent on SIM1 alone, SIM3 and 4 in
combination, or SIM2, 3 and 4 in combination. Interestingly, the interaction of
Slx5 with Siz1 closely mirrors the interaction with SUMO, suggesting that Siz1
may be a STUbL substrate. The only difference was that the Slx5*Siz1 interaction
could not take place with the presence of SIM1 alone but required SIM1 and 2 in
combination. Furthermore, when a construct of Slx5 missing SIM1 and 2 (sim-A/
B Slx5) was tested with SUMO and Siz1 the interactions were abolished. We
concluded the region of Slx5 from amino acid 1-207 constitutes a SUMO/
substrate interaction domain.
Based upon these data it can be suggested that the interaction is SIM
dependent. It has been suggested that Slx5 depends on the composite and
redundant function of SIM1-4 for interaction with SUMO in vivo, in accordance
with our data (Xie et al., 2010). Curiously, the known degradation of the MATa2
repressor by the Slx5/Slx8 STUbL is a SUMO independent process. However,
the degradation of MATa2 by Slx5/Slx8 is dependent on SIM1-4. The activities
between Slx5 and MATa2 prompt two important questions about the interaction
between Slx5 and Siz1. First, it seems that the interaction requires SIMs in Slx5

46

but it is yet to be determined whether sumoylation of Siz1 is required. Siz1 is
autosumoylated in vivo, yet any self-regulation by this modification has not been
elucidated (Zhou et al., 2004)). The second question is whether or not Siz1, like
MATa2, may contain a SUMO like domain that is recognized by the Slx5/Slx8
STUbL(Xie et al., 2010).
The second domain characterized by this study is the Slx8 binding domain of
Slx5. Only one Slx5 C-terminal truncation, Slx5(1-517), retaining two cysteine
residues (Cys494 and Cys497) of the RING domain, showed a reproducible but
weaker interaction with Slx8. None of the Slx5 amino-terminal truncations
showed interaction with Slx8. Surprisingly, the one feature present in the
Slx5(1-517) truncation that was absent from the opposite N-terminal truncation,
Slx5(50-620), was SIM1. This suggests that at least 50 residues of the aminoterminus, including SIM 1, but not the entire RING domain of Slx5 is required for
interaction with Slx8. The RING domain of Slx5, containing a protein dimerization
domain, is necessary for suppression of synthetic lethality with the DNA helicase
Sgs1 ( Mullen and Brill, 2008). Also, the RING domains of both Slx5 and Slx8 are
required for cellular DNA damage resistance ( Xie et al., 2007). While it is known
that the Slx8 RING domain confers ubiquitin ligase activity little is known about
the activity of the Slx5 RING domain. It has been shown that the RING domain of
Slx5 enhances the activity of the Slx8 ubiquitylation. Due to this enhanced
activity it has been suggested that the Slx5 RING domain may act to stabilize the
Slx8 RING domain in an active confirmation ( Xie et al., 2007).

Since SIM1 is

required for Slx5*Slx8 interaction and given that Slx8 can also bind SUMO in vitro
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(Mullen and Brill, 2008), it is tempting to speculate that SUMO recognition by
both Slx5 and Slx8, along with the RING domain,

may play a role in the

heterodimer association and orientation. Importantly, the human ortholog of the
Slx5/Slx8 complex, RNF4, requires RING domain dimerization for ubiquitylation
of targets and the protein contains SIMs.
Finally, a nuclear localization/homodimerization domain was identified in this
study. The domain of Slx5 from amino acid 207-310 was required for both the
nuclear localization of Slx5 and the Slx5*Slx5 two-hybird interaction. The domain
207-310 was involved in nuclear localization and Slx5 constructs lacking this
domain formed cytosolic aggregates in the cell. One possible explanation of this
finding is that homodimerization is required for nuclear import or nuclear retention
of Slx5. Several examples of proteins that require dimerization for nuclear import
exist (Fryrear et al., 2009, Hayes et al., 2009).

It is tempting to speculate that

homodimerization of Slx5 may also prevent the premature association of this
STUbL subunit with sumoylated proteins in the cytosol. Currently, it is unknown
how Slx5 and Slx8 enter the nucleus. Further investigation will determine if there
is a dynamic regulation of Slx5 and Slx8 between the nucleus and cytosol.

Does Slx5/Slx8 have a role in the cytosol?
Several other nuclear members of the SUMO pathway are dynamically
exported into the cytosol in a cell cycle specific manner. These SUMO pathway
components include the SUMO protease Ulp1 and the SUMO E3 ligase Siz1
(Makhnevych et al., 2007). As mentioned above, Ulp1 and Siz1 regulate the
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sumoylation state of the bud-neck septin proteins during G2/M and cytokinesis.
A role for Slx5/Slx8 outside of the nucleus is not an unprecedented concept.
Unpublished data in the Kerscher lab suggest that cells lacking the nucleoporin
Nup170 exhibit diffuse nuclear and cytosolic staining of wild-type Slx5-GFP.
Accordingly, GFP truncations of Slx5 lacking the nuclear localization/
homodimerization domain from this study also show diffuse intracellular staining.
Whether or not Slx5/Slx8 plays a role in the cytosol is yet to be determined.
However, given the observed cytosolic localization of Slx5, the novel interaction
with Siz1 described in this study, and the extensive evidence suggesting a role
for Slx5 and Slx8 in the SUMO pathway (see INTRODUCTION: Slx5/Slx8 and
the SUMO pathway), further investigation into a hypothesis suggesting a role for
Slx5/Slx8 in regulating levels of sumoylated proteins is worthwhile. Experiments
addressing how Slx5 may interact with nucleoporins and/or karyopherins may be
a good platform to further our understanding.

Does Slx5 potentiate Siz1 sumoylation activity in the cytosol?
Several lines of evidence presented in this study indicate that Slx5 may
potentiate the sumoylation activity of Siz1 in the cytosol of yeast cells. First, Slx5
and Siz1 interact genetically in a two-hybrid assay and physically in in vivo
pulldown assays. Second, Slx5 and Slx8 physically interact with Siz1

in vitro.

Third, in slx5A cells arrested at G2/M there are reduced levels of Siz1 and
SUMO-Cdc3 conjugates at the bud-neck. Lastly, Siz1 is an in vitro ubiquitylation
target of the Slx5/Slx8 STUbL. Based on these data we hypothesize that the
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SUMO E3 ligase Siz1 may be a ubiquitylation substrate of the Slx5/Slx8 STUbL
and that Slx5/Slx8 may regulate the cytosolic sumoylation activity of Siz1.
It has been previously reported that Siz1 is auto-sumoylated in vivo, however
the downstream effects of this modification are unknown (Zhou et al., 2004). It
has also been reported that the overexpression of Siz1 leads to a counter
intuitive decrease in the level of sumoylated septins (Takahashi et al., 2001). In
order to extrapolate upon our hypothesis that Siz1 is a substrate of the Slx5/Slx8
STUbL, with the previous literature in mind, we propose two potential models to
describe the mechanism resulting in reduced levels of sumoylated-Cdc3 and
Siz1 at the bud-neck in slx5A cells during G2/M.
In the first model, we propose that the ubiquitylation of Siz1 by the Slx5/Slx8
STUbL could lead to its nuclear export (Figure 10). Other cases have been
described in which ubquitylation leads to export from the nucleus (as detailed
above in the Introduction). The auto-sumoylation of Siz1 in vivo makes it an ideal
candidate for STUbL mediated ubiquitylation. In concept, the ubiquitylation of
Siz1 could lead to exposure of a nuclear export signal (NES), and once in the
cytosol Siz1 would proceed to sumoylating the septin proteins. Perhaps the prior
sumoylation of Siz1 masks the NES, retaining Siz1 in the nucleus and illustrating
the sequential regulatory relationship between SUMO and ubiquitin modification
described in other pathways. Deletion of SLX5 in this context would result in a
pool of sumoylated Siz1 that is trapped in the nucleus and thus could not perform
its function at the septin ring. Such a phenomenon is supported, in part, by the
observed decrease in Siz1 at the bud-neck as well as decreased SUMO-Cdc3
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levels at G2/M of the cell cycle. If such a model held true, one could speculate
that the over expression of Siz1 may overwhelm the cells ability to ubiquitylate
the molecule causing buildup, and perhaps aggregation, of SUMO-Siz1
conjugates in the nucleus of the cell. In turn, this buildup of SUMO-Siz1 in the
nucleus would result in the reported decrease of septin sumoylation when Siz1 is
over-expressed (Takahashi et al., 2008).

Figure 10. Putative model for the regulation of Siz1 by the Slx5/Slx8 STUbL.
A) In wild-type cells we propose that Slx5/Slx8 (green rectangles) may be
targeted to sumoylated Siz1 (orange Siz1 sphere & white SUMO sphere) in the
nucleus (Light blue sphere), leading to its ubiquitylation (dark blue sphere) (arrow
1). The ubiquitylation of Siz1 may potentiate the export of Siz1 to the cytosol,
lead to degradation of Siz1 by the proteasome, or both (arrow 2). B) Cells
deficient in Slx5 can no longer regulate Siz1 appropriately, putatively resulting in
a build-up of sumoylated Siz1 in the nucleus.
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In the second model we propose that the ubiquitylation of Siz1 by the Slx5/
Slx8 STUbL could lead to its proteasomal degradation (Figure 10). If Slx5/Slx8
regulates the amount of Siz1 in the cell then it could be suggested that deletion
of SLX5 would result in a situation similar to that presented in model one.
Deletion of Slx5, in the context of Siz1 degradation, would result in an effective
over-expression of Siz1. Over expression of Siz1 could lead to nuclear buildup of
the protein, presumably the sumoylated form, and the observed decreased septin
sumoylation. Currently there is not evidence illustrating a build-up of Siz1 in the
nucleus.
In order to elucidate the details of the Siz1-Slx5 relationship additional key
experiments are under way. To determine if Siz1 is being degraded by the Slx5/
Slx8 STUbL we are

conducting a cycloheximide-chase assay, in which potein

synthesis is halted. If Siz1 is a degradation target of Slx5/Slx8 then the level of
Siz1, after addition of cycloheximide ,would stabilize in slx5A cells. While we
know that Siz1 can be ubiquitylated in vitro, observation of in vivo ubiquitylation
would complement the cycloheximide-chase assay and provide additional
support for the data shown here. Other compelling experiments include
examining the sumoylation or ubquitylation of Siz1 in different cellular
compartments (i.e. nuclear vs. cytosolic) at different stages of the cell cycle.
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Summary and impact
Our structure function analysis of Slx5 has not only provided insight into the
domains responsible for the nuclear localization and protein interaction within this
STUbL subunit, but it has also given us a tool box for the discovery of new Slx5
interactors. For example, one of the most remarkable observations of the current
study is the influence of Slx5 on the SUMO E3 ligase Siz1, an observation that
resulted directly from our studies. The interaction of RNF4 with PIAS1, the
human orthologs of Slx5 and Siz1 respectively, emphasizes the conserved
nature of these cellular mechanisms from yeast to humans and underscores the
importance of our research in the budding yeast model system.
The possible regulation of a SUMO E3 ligase by a STUbL implies a novel and
exciting crosstalk between the SUMO and ubiquitin systems. The implications of
such regulation may have profound effects on our understanding of SUMO
biology. The regulation of sumoylation by STUbLs would no longer be limited to
modification and degradation of specific target proteins, but would extend to the
regulation of enzymes responsible for SUMO modification. Control of
sumoylation in this context would allow STUbLs to regulate sumoylated targets
on a global scale, simultaneously regulating the processes of transcription, DNA
repair, cell cycle control and many others. For example, the regulation of SUMO
conjugation machinery would broaden the scope of STUbL activity in the cell,
implicating STUbLs in the fate of countless sumoylation targets and essential
cellular pathways.
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An example of the new perspective this study reveals is illustrated by the
tumor suppressor protein p53. p53 is an in vivo sumoylation target of PIAS1, the
human ortholog of Siz1 (Kahyo et al., 2001). The sumoylation of p53 recruits the
protein to PML bodies, and sumoylation of p53 on K386 stimulates its
transcriptional activity. The stimulation of activity could result from an increased
affinity of p53 for DNA or perhaps the localization and sequestration of p53 in the
nucleus at PML bodies (Gostissa et al., 1999; Rodriguez et al., 1999). Microarray
analysis suggests that p53 is responsible for the regulation of over 100 genes
with important roles in regulation of the cell cycle, tumor suppression and DNA
damage; it is for this reason that it is called the “guardian of the genome” (Allison,
2007). Mutations in the p53 gene are linked to many types of cancer. Further,
bioinformatic studies suggest that there are potential p53 binding sites in greater
than 4,000 human genes (Allison, 2007). The concept that PIAS1 sumoylation of
p53, and p53 transcriptional activity, could be indirectly regulated by STUbLs is
groundbreaking and far-reaching.
The putative implication for p53 regulation is just one example of the effects
that this novel crosstalk between the SUMO and ubiquitin pathways may have on
cellular sumoylation targets. Without a doubt, in the next few years many more
exciting details of a potential feedback loop between SUMO ligation and SUMO
mediated degradation will emerge.
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Supplementary Figure 1. Additional two-hybrid data. A) SIM1 and 2 in Slx5
were not essential for interaction of Slx5 with other Slx5 proteins, however,
interaction of Slx5 with Slx8 was reduced and interaction with Smt3 was
abolished. B) SIM1 and 2 of Slx5 were essential for the interaction with Siz1. C)
Siz1 and Slx8 do not interact in a two-hybrid assay. Interactions were scored as
growth on media lacking adenine.
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Supplementary Figure 2. A recent observation suggests that the STUbL Hex3/
Slx8 complex may interact with double stranded DNA breaks that reside in close
proximity to nuclear pore complexes (Nagai et al., 2009). In order to test this
hypothesis we generated a nup133A NIC96-RFP strain. In this strain deletion of
NUP133, a nucleoporin with a role in the even distribution of nuclear pore
complexes, results in clusters of the RFP tagged nucleoporin Nic96.
Subsequently, the nup133A NIC96-RFP strain was transformed with a construct
expressing Slx5-GFP. The ultimate goal of these studies is to determine if in live
cells Slx5-GFP foci can overlap with clustered Nic96-RFP nucleoporins. Co
localization of Slx5 and Nic96 could suggest that STUbLs may interact with
nucleoporins and dsDNA breaks in the vicinity of nuclear pore complexes. Initial
results suggest that Slx5 foci and NPC foci do not overlap in either wild-type or
nup133A strains when exposed to Zeocin induced DNA damage. We aim to
verify these data in a yeast strain that contains only a single induced dsDNA
break. Additionally, we would like to generate three dimensional confocal images
of Slx5 foci in yeast cell nuclei.
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Supplementary Table 1. Strains and plasmids used in this study
Name

Pertinent
Genotypes or
Parent Strains

Plasmids

Reference

YOK1220

AH109
(Clontech
Laboratories
Inc.)

YOK1221

AH109 & Y187
(Clontech
Laboratories
Inc.)

YOK1322

Mata his3A1
leu2A0
m e tl 5A0
ura3A0
(BY4741)

YOK1364

CDC3-YFP/
HIS5 (BY4741)

SLX5(1 -207)-GFP/LEU2
(BOK507)

This study

YOK1369

YOK1322
(BY4741)

SLX5(1 -50)-GFP/LEU2
(BOK514)

This study

YOK1370

YOK1322
(BY4741)

SLX5(1 -104)-GFP/LEU2
(BOK515)

This study

YOK1372

YOK1322
(BY4741)

SLX5(1 -310)-GFP/LEU2 (BOK517)

This study

YOK1373

YOK1322
(BY4741)

SLX5(1 -414)-GFP/LEU2 (BOK518)

This study

YOK1374

YOK1322
(BY4741)

SLX5(1 -517)-GFP/LEU2 (BOK519)

This study

YOK1375

YOK1322
(BY4741)

SLX5(1 -207)-GFP/LEU2
(BOK507)

This study

YOK1397

slx5A::G418
CDC3-YFP/
HIS5 (M HY501,
BY4741)

This study

YOK1398

slx5A::G418
CDC3-YFP/
HIS5 (M HY501,
BY4741)

This study

(Clontech
Laboratories
Inc.)

pGBKT7-53 & pGADT7-T (Clontech
Laboratories Inc.)

(Clontech
Laboratories
Inc.)

Openbio
Systems
Inc.
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Name

Pertinent
Genotypes or
Parent Strains

Plasmids

Reference

YOK1408

AH109

SLX5(1 -104)-BD/TRP;
SLX5-AD/LEU2 (BOK289)

This study

YOK1411

AH109

SLX5(1 -207)-BD/TRP;
SLX5-AD/LEU2 (BOK289)

This study

YOK1414

AH 109

SLX5(1-310)-BD/TRP;
SLX5-AD/LEU2 (BOK289)

This study

YOK1417

AH 109

SLX5(1-414)-BD/TRP;
SLX5-AD/LEU2 (BOK289)

This study

YOK1420

AH 109

SLX5(1 -517)-BD/TRP;
SLX5-AD/LEU2 (BOK289)

This study

YOK1423

AH109

SLX5(51 -620)-BD/TRP;
SLX5-AD/LEU2 (BOK289)

This study

YOK1425

AH 109

SLX5(105-620)-BD/TRP;
SLX5-AD/LEU2 (BOK289)

This study

YOK1428

AH109

SLX5(208-620)-BD/TRP;
SLX5-AD/LEU2 (BOK289)

This study

YOK1431

AH109

SLX5(311-620)-BD/TRP;
SLX5-AD/LEU2 (BOK289)

This study

YOK1434

AH109

SLX5(415-620)-BD/TRP;
SLX5-AD/LEU2 (BOK289)

This study

YOK1437

AH109

SLX5(1 -104)-BD/TRP;
SLX8-AD/LEU2 (BOK311)

This study

YOK1440

AH109

SLX5(1 -207)-BD/TRP;
SLX8-AD/LEU2 (BOK311)

This study

YOK1443

AH109

SLX5(1-310)-BD/TRP;
SLX8-AD/LEU2 (BOK311)

This study

YOK1446

AH 109

SLX5(1-414)-BD/TRP;
SLX8-AD/LEU2 (BOK311)

This study

YOK1449

AH 109

SLX5(1-517)-BDfrRP;
SLX8-AD/LEU2 (BOK311)

This study

YOK1452

AH109

SLX5(51 -620)-BD/TRP;
SLX8-AD/LEU2 (BOK311)

This study

YOK1455

AH109

SLX5(105-620)-BD/TRP;
SLX8-AD/LEU2 (BOK311)

This study
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Name

Pertinent
Genotypes or
Parent Strains

Plasmids

Reference

YOK1458

AH109

SLX5(208-620)-BD/TRP;
SLX8-AD/LEU2 (BOK311)

This study

YOK1461

AH 109

SLX5(311-620)-BD/TRP;
SLX8-AD/LEU2 (BOK311)

This study

YOK1464

AH 109

SLX5(415-620)-BD/TRP;
SLX8-AD/LEU2 (BOK311)

This study

YOK1467

AH 109

SLX5-BD/TRP (BOK440);
SIX5-AD/LEU2 (BOK289)

This study

YOK1470

AH109

SLX5-BD/TRP (BOK440);
SLX8-AD/LEU2 (BOK311)

This study

YOK1491

AH 109

SLX5-BD/TRP (BOK440);
SU M 02-AD /LEU 2 (BOK447)

This study

YOK1494

AH 109

SLX5-BD/TRP (BOK440);
PIAS1-AD/LEU2 (BOK558)

This study

YOK1497

AH 109

RNF4-BD/TRP (BOK556);
SU M 02-AD/LEU 2 (BOK447)

This study

YOK1500

AH109

RNF4-BD/TRP (BOK556);
PIAS1-AD/LEU2 (BOK558)

This study

YOK1503

AH 109

RNF4-BD/TRP (BOK556);
SU M 02-AD /LEU 2 (BOK447)

This study

YOK1506

AH 109

RNF4cs-BD/TRP (BOK557);
PIAS1-AD/LEU2 (BOK558)

This study

YOK1518

AH109

SLX5-BD/TRP (BOK440);
SMT3-AD/LEU2 (BOK571)

This study

YOK1522

YOK1322
(BY4741)

SLX5(1 -207)SIMA/B-GFP/LEU2

This study

YOK1547

AH 109

SLX5(1 -50)-BD/TRP
SMT3-AD/LEU2 (BOK571)

This study

YOK1550

AH 109

SLX5(1 -104)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study

YOK1553

AH 109

SLX5(1 -207)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study

YOK1556

AH 109

SLX5(1 -310)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study
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Name

Pertinent
Genotypes or
Parent Strains

Plasmids

Reference

YOK1559

AH109

SLX5(1-414)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study

YOK1562

AH109

SLX5(1-517)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study

YOK1565

AH109

SLX5(51-620)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study

YOK1568

AH 109

SLX5(311-620)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study

YOK1571

AH109

SLX5(208-620)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study

YOK1574

AH 109

SLX5(311-620)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study

YOK1577

AH 109

SLX5(415-620)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study

YOK1580

AH109

SLX5(518-620)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study

YOK1583

AH109

SLX5(518-620)-BD/TRP;
SLX8-AD/LEU2 (BOK311)

This study

YOK1586

AH109

SLX5(518-620)-BD/TRP;
SLX5-AD/LEU2 (BOK289)

This study

YOK1589

AH109

SLX5(1 -50)-BD/TRP
SLX8-AD/LEU2 (BOK311)

This study

YOK1592

AH109

SLX5(1 -50)-BD/TRP
SLX5-AD/LEU2 (BOK289)

This study

YOK1595

AH 109

SLX5-BD/TRP (BOK440);
SIZ1-AD/LEU2 (BOK582)

This study

YOK1621

AH109

SLX5(1 -50)-BD/TRP
SIZ1-AD/LEU2 (BOK582)

This study

YOK1625

AH 109

SLX5(1 -104)-BD/TRP;
SIZ1-AD/LEU2 (BOK582)

This study

YOK1627

AH109

SLX5(1 -207)-BD/TRP;
SIZ1-AD/LEU2 (BOK582)

This study

YOK1630

AH109

SLX5(1 -310)-BD/TRP;
SIZ1-AD/LEU2 (BOK582)

This study
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Name

Plasmids

Pertinent
Genotypes or
Parent Strains

Reference

YOK1633

AH109

SLX5(1-414)-BD/TRP;
SIZ1-AD/LEU2 (BOK582)

This study

YOK1636

AH 109

SLX5(1 -517)-BD/TRP;
SIZ1-AD/LEU2 (BOK582)

This study

YOK1639

AH109

SLX5(51 -620)-BD/TRP;
SIZ1-AD/LEU2 (BOK582)

This study

YOK1642

AH109

SLX5(311-620)-BD/TRP;
SIZ1-AD/LEU2 (BOK582)

This study

YOK1645

AH109

SLX5(208-620)-BD/TRP;
SIZ1-AD/LEU2 (BOK582)

This study

YOK1648

AH 109

SLX5(311-620)-BD/TRP;
SIZ1-AD/LEU2 (BOK582)

This study

YOK1651

AH109

SLX5(415-620)-BD/TRP;
SIZ1-AD/LEU2 (BOK582)

This study

YOK1654

AH 109

SLX5(518-620)-BD/TRP;
SIZ1-AD/LEU2 (BOK582)

This study

YOK1791

AH109

SLX8-AD/LEU2 (BOK311)

This study

YOK1792

AH 109

SIX5-AD/LEU2 (BOK289)

This study

YOK1793

AH109

SLX5(SIMAB)-BD/TRP;
SIX5-AD/LEU2 (BOK289)

This study

YOK1794

AH 109

SLX5(SIMAB)-BD/TRP;
SIX5-AD/LEU2 (BOK289)

This study

YOK1795

AH 109

SLX5(SIMAB)-BD/TRP;
SIX5-AD/LEU2 (BOK289)

This study

YOK1796

AH109

SLX5(SIMAB)-BD/TRP;
SIX8-AD/LEU2 (BOK311)

This study

YOK1797

AH 109

SLX5(SIMAB)-BD/TRP;
SIX8-AD/LEU2 (BOK311)

This study

YOK1798

AH 109

SLX5(SIMAB)-BD/TRP;
SIX8-AD/LEU2 (BOK311)

This study

YOK1799

AH 109

SLX5(SIMAB)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study
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Pertinent
Genotypes or
Parent Strains

Plasmids
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YOK1800

AH109

SLX5(SIMAB)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study

YOK1801

AH 109

SLX5(SIMAB)-BD/TRP;
SMT3-AD/LEU2 (BOK571)

This study

YOK1830

MHY500

SLX5(208-310)-GFP/LEU2
(BOK637)

This study

YOK1890

slx5A::G418
SIZ1-GFP

This study

YOK1891

SIZ1-GFP

This study

YOK1894

SIZ1-GFP

This study

YOK1895

slx5A::G418
SIZ1-GFP

This study

YOK1898

SIZ1-GFP

This study

YOK1901

slx5A::G418
SIZ1-GFP

This study

YOK2017

AH 109

SLX5-BD/TRP (BOK440);
EMPTY-AD/LEU2 (BOK312)

This study

YOK2018

AH109

RNF4-BD/TRP (BOK556);
EMPTY-AD/LEU2 (BOK312)

This study

YOK2019

AH109

RNF4cs-BD/TRP (BOK557);
EMPTY-AD/LEU2 (BOK312)

This study

YOK2020

AH109

EMPTY-BD/TRP (BOK313)
SMT3-AD/LEU2 (BOK571)

This study

YOK2021

AH 109

EMPTY-BD/TRP (BOK313)
SIZ1-AD/LEU2 (BOK582)

This study

YOK2022

AH 109

EMPTY-BD/TRP (BOK313)
S U M 02-AD /LEU 2 (BOK447)

This study

YOK2023

AH 109

EMPTY-BD/TRP (BOK313)
PIAS1-AD/LEU2 (BOK571)

This study

YOK2037

YOK1398

SMT3gg-FLAG/LEU2 (BOK700)

This study

YOK2038

YOK1397

SMT3gg-FLAG/LEU2 (BOK700)

This study
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Name

Pertinent
Genotypes or
Parent Strains

Plasmids

Reference

YOK2072

JD52 (MATa
his3-200
Ieu2-3,112
Iys2-801 trp1 -63
ura3-52)

YOK2091

CDC3-YFP/
HIS5
YOK1322
(BY4741)

This study

YOK2092

msn5A, CDC3YFP/HIS5
(BY4741)

This study

YOK2093

slx8A, CDC3YFP/HIS5
(BY4741)

This study

YOK2094

slx5A, CDC3YFP/HIS5
(BY4741)

This study

YOK2095

siz1 A, CDC3YFP/HIS5
(BY4741)

This study

YOK2104

AH109

SIX5-AD/LEU2 (BOK289)

This study

YOK2105

AH 109

SIZ1-BD/TRP (BOK599)

This study

YOK2106

AH 109

SIZ1-AD/LEU2 (BOK582)

This study

YOK2107

AH 109

SLX5(SIMAB)-BD/TRP (BOK627)

This study

Y0K2111

AH 109

SLX5(SIMAB)-BD/TRP (BOK627);
SIZ1-AD/LEU2 (BOK582)

This study

YOK2112

AH109

SLX5(SIMAB)-BD/TRP (BOK627);
SIZ1-AD/LEU2 (BOK582)

This study

YOK2113

AH 109

SLX5(SIMAB)-BD/TRP (BOK627);
SIZ1-AD/LEU2 (BOK582)

This study

YOK2196

MYC-SIZ1
(YHU2107)

SLX5(1 -310)-GFP/LEU2 (BOK517)

This study

GST-SLX5/URA (BOK629);
SIZ1-HIS/FLAG/TRP (BOK732)

63

Ju et al.,
2008 &
Openbio
Systems
Inc.

Plasmids used for bacterial production of recombinant protein

480

His6-HsUbc4

Ubiquitin E2

-

500 BL21(DE3)s +MBP-Slx5

-

This Study

501 BL21(DE3)s + MBP-Slx8

-

This Study

pT-77 (AmpR) From AddGene Takahashi et al.,
2005
758 *Rs + T7-Siz1 A440-His
BOK 591
This Study
591

T7-Siz1 A440-His
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